Cautious Now, Optimistic Future
8:48–9:45 · 57s
Amid regulatory cost-effectiveness pushback, Spires-Jones says next-gen drugs look safer and better, research is moving beyond amyloid, and she’s optimistic about life-changing treatments within a decade.